8. The anti-IL-25 antibody according to claim **1**, which is an antibody fragment that binds (human) IL-25, preferably selected from the group consisting of Fv, Fab, Fab-SH, Fab'-SH, Fab', Fab-C, Fab'-C, Fab'-C—SH, Fab-C—SH, scFv, diabody, or $F(ab')_2$; diabodies; linear antibodies; single-chain antibody molecules (e.g. scFv); and multispecific antibodies formed from antibody fragments.

9. An isolated nucleic acid encoding the antibody of claim **1**.

10. A host cell comprising the nucleic acid of claim **9**.

11. A method of producing the antibody of claim **1** comprising culturing the host cell of claim **10** so that the antibody is produced.

12. A pharmaceutical composition comprising the antibody of claim **1** and a pharmaceutically acceptable carrier.

13. A method of treating diseases associated with IL-25 in a subject comprising administering to the subject an effective amount of the antibody of claim **1**, the nucleic acid of claim **9**, the host cell of claim **10** or the pharmaceutical composition of claim **12**.

14. The method according to claim **13**, wherein the subject is a mammal, preferably rat, mouse, monkey, or human.

15. The method according to claim **13**, wherein the diseases associated with IL-25 are selected from autoimmune disorders, inflammatory diseases or cancers wherein IgE, IL-4, IL-5 and/or IL-13 are overexpressed/overproduced, preferably allergic (inflammatory) diseases, and more preferably selected from asthma (e.g., allergic asthma), atopic dermatitis, atopic allergic diseases, allergic rhinitis, hay fever, allergic conjunctivitis, eczema, food allergies, psoriasis, psoriatic arthritis, ankylosing spondylitis, rheumatoid arthritis (RA), multiple sclerosis (MS), systemic lupus, osteoarthritis or inflammatory bowel disorder (IBD).

16-17. (canceled)

* * * * *